Immunogenicity of a Single Dose of Tetravalent Meningococcal Serogroups A, C, W-135, and Y Conjugate Vaccine Administered to 2- to 10-year-olds Is Noninferior to a Licensed-ACWY Polysaccharide Vaccine With an Acceptable Safety Profile

Background: Meningococcal disease remains an important cause of invasive bacterial infections in children less than 5 years of age. Immunogenicity and safety of the investigational ACWY vaccine conjugated with tetanus toxoid (ACWY-TT, GlaxoSmithKline Biologicals) were evaluated in 1501 healthy 2- to 10-year-old children in the Philippines, India, Lebanon, and Saudi Arabia. Methods: Children were randomized (3:1) to receive ACWY-TT or licensed tetravalent meningococcal polysaccharide vaccine (Mencevax, GlaxoSmithKline, Men-PS). Diary cards were used to collect solicited symptoms for 4 days after vaccination. Serious adverse events were reported for 6 months. Serum bactericidal activity (rSBA, rabbit complement) was measured before and 1 month after vaccination in the first 75% of subjects enrolled in each country. Results: The statistical criteria for noninferiority in terms of rSBA vaccine responses were reached. Exploratory analyses showed that postvaccination rSBA titers ≥1:8 and ≥1:128 were significantly higher after ACWY-TT than Men-PS for serogroups C, W-135, and Y, and rSBA vaccine responses and geometric mean antibody titers were significantly higher for all 4 serogroups after administration of ACWY-TT. Noninferiority in terms of incidences of grade 3 general symptoms was not demonstrated. ACWY-TT was well tolerated with grade 3 events reported in <1% of subjects per group. No serious adverse events were considered related to vaccination. Conclusion: ACWY-TT was immunogenic in children between 2 to 10 years of age with a clinically acceptable safety profile that resembled licensed Men-PS. These data support a positive benefit/risk ratio for the ACWY-TT vaccine.

[1]  A. Pollard,et al.  The epidemiology of meningococcal disease and the impact of vaccines , 2010, Expert review of vaccines.

[2]  W. Schaffner,et al.  Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  J. Poolman,et al.  A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. , 2010, Vaccine.

[4]  K. Reisinger,et al.  Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  Lee H Harrison,et al.  Global epidemiology of meningococcal disease. , 2009, Vaccine.

[6]  S. Gupta,et al.  Ciprofloxacin-Resistant Neisseria meningitidis, Delhi, India , 2007, Emerging infectious diseases.

[7]  N. Gogtay,et al.  Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. , 2007, Vaccine.

[8]  R. Hajjeh,et al.  The epidemiology of pneumococcal, meningococcal, and Haemophilus disease in the Middle East and North Africa (MENA) region--current status and needs. , 2007, Vaccine.

[9]  S. Chanteau,et al.  Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  H. Keyserling,et al.  Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. , 2005, Archives of pediatrics & adolescent medicine.

[11]  E. Miller,et al.  Meningococcal surrogates of protection--serum bactericidal antibody activity. , 2005, Vaccine.

[12]  M. Patel,et al.  Polysaccharide vaccines for preventing serogroup A meningococcal meningitis. , 2005, The Cochrane database of systematic reviews.

[13]  M. Pichichero,et al.  Comparative Trial of the Safety and Immunogenicity of Quadrivalent (A, C, Y, W-135) Meningococcal Polysaccharide-Diphtheria Conjugate Vaccine Versus Quadrivalent Polysaccharide Vaccine in Two- to Ten-Year-Old Children , 2005, The Pediatric infectious disease journal.

[14]  A. Pollard.  Global Epidemiology of Meningococcal Disease and Vaccine Efficacy , 2004, The Pediatric infectious disease journal.

[15]  Y. Al-Mazrou,et al.  Disease burden and case management of bacterial meningitis among children under 5 years of age in Saudi Arabia. , 2003, Saudi medical journal.

[16]  N. Andrews,et al.  Validation of Serological Correlate of Protection for Meningococcal C Conjugate Vaccine by Using Efficacy Estimates from Postlicensure Surveillance in England , 2003, Clinical Diagnostic Laboratory Immunology.

[17]  K. Goh,et al.  Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  N. Andrews,et al.  Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis , 2003, BMJ : British Medical Journal.

[19]  J. T. Koama,et al.  Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso. , 2002, The Lancet. Infectious diseases.

[20]  Fonkoua Mc.  Meningococcal meningitis in Africa. , 2002, Releve epidemiologique hebdomadaire.

[21]  M. Achtman,et al.  Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana. , 2002, The Journal of infectious diseases.

[22]  R. Kanungo,et al.  Childhood bacterial meningitis in Pondicherry, South India , 2001, Indian journal of pediatrics.

[23]  K. Cartwright,et al.  Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines. Report of a European advisory board meeting Vienna, Austria, 6-8 October, 2000. , 2001, Vaccine.

[24]  T. Popović,et al.  The changing epidemiology of meningococcal disease in the United States, 1992-1996. , 1999, The Journal of infectious diseases.

[25]  B. Greenwood,et al.  Manson Lecture. Meningococcal meningitis in Africa. , 1999, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[26]  J. Taylor,et al.  Efficacy of meningococcal vaccine and barriers to vaccination. , 1998, JAMA.

[27]  G. Carlone,et al.  Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group , 1997, Clinical and diagnostic laboratory immunology.

[28]  Meningitis in Chad, Niger and Nigeria: 2009 epidemic season. , 2010, Releve epidemiologique hebdomadaire.

[29]  Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP), 2010. , 2010, MMWR. Morbidity and mortality weekly report.

[30]  J. Poolman,et al.  Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. , 2009, Vaccine.

[31]  Inadvertent misadministration of meningococcal conjugate vaccine--United States, June-August 2005. , 2006, MMWR. Morbidity and mortality weekly report.

[32]  D. Goldblatt,et al.  Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. , 2001, The Journal of infectious diseases.

[33]  S. Jaffar,et al.  Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. , 1997, The Journal of infectious diseases.

[34]  G. Carlone,et al.  Standardization and a Multilaboratory Comparison ofNeisseria meningitidisSerogroup A and C Serum Bactericidal Assays , 1997 .

[35]  Peltola,et al.  Control of Epidemic Meningococcal Disease. Who Practical Guidelines. 2 World Health Organization Emerging and Other Communicable Diseases, Surveillance and Control Editorial Working Group Preface (edition 1) Preface (edition 1) , 2022 .